Phibro Animal Health (PAHC) to pay $0.12 on Mar 27, 2019; Btg Pactual Global Asset Management LTD Has Cut Agios Pharmaceuticals (AGIO) Position By $442,596

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Logo

Btg Pactual Global Asset Management Ltd decreased Agios Pharmaceuticals Inc (AGIO) stake by 66.95% reported in 2018Q3 SEC filing. Btg Pactual Global Asset Management Ltd sold 5,748 shares as Agios Pharmaceuticals Inc (AGIO)’s stock declined 29.17%. The Btg Pactual Global Asset Management Ltd holds 2,838 shares with $219,000 value, down from 8,586 last quarter. Agios Pharmaceuticals Inc now has $3.14 billion valuation. The stock decreased 1.39% or $0.76 during the last trading session, reaching $54.03. About 393,647 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has declined 13.33% since February 14, 2018 and is downtrending. It has underperformed by 13.33% the S&P500. Some Historical AGIO News: 28/03/2018 – IMMUNOVACCINE ANNOUNCES INITIATION OF PATIENT DOSING IN INVESTIGATOR-SPONSORED PHASE 2 CLINICAL TRIAL OF ITS LEAD CANDIDATE DPX-SURVIVAC USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH DLBCL; 23/05/2018 – MERCK & CO – SUBMITTED SBLA FOR KEYTRUDA IN COMBINATION TO U.S. FDA AND NEW DATA WILL BE SHARED WITH AGENCY; 09/04/2018 – Merck: Keytruda Significantly Improves Overall Survival in Study; 26/04/2018 – Opdivo Drives Bristol-Myers Growth — Earnings Review; 07/05/2018 – PROVECTUS BIOPHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMA; 31/05/2018 – Medivir: Phase I/II study design of birinapant in combination with Keytruda® to be presented on June 4 at the ASCO Annual Meeting; 16/04/2018 – BRISTOL-MYERS: OPDIVO PHASE 3 SHOWED BENEFIT FOR PRIMARY ENDPT; 04/05/2018 – AGIOS 1Q LOSS/SHR $1.63, EST. LOSS/SHR $1.63; 30/04/2018 – Merck Seeks Approval for Keytruda Combo as First-Line Treatment for Metastatic Nonsquamous NSCLC; 15/03/2018 – Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 Ameri

Phibro Animal Health Corp (NASDAQ:PAHC) is expected to pay $0.12 on Mar 27, 2019. (NASDAQ:PAHC) shareholders before Mar 5, 2019 will receive the $0.12 dividend. Phibro Animal Health Corp’s current price of $28.80 translates into 0.42% yield. Phibro Animal Health Corp’s dividend has Mar 6, 2019 as record date. Feb 6, 2019 is the announcement. The stock decreased 1.64% or $0.48 during the last trading session, reaching $28.8. About 150,325 shares traded or 12.33% up from the average. Phibro Animal Health Corporation (NASDAQ:PAHC) has risen 1.26% since February 14, 2018 and is uptrending. It has outperformed by 1.26% the S&P500. Some Historical PAHC News: 10/05/2018 – Phibro Events and Innovations Expand Dairy Industry Collaboration, Knowledge of DCAD Nutrition; 14/03/2018 Phibro Animal Forms Golden Cross: Technicals; 03/04/2018 – Phibro Animal Health Corporation to Host Webcast and Conference Call on March 2018 Quarterly Financial Results; 07/05/2018 – Phibro Animal Health Corporation Declares Quarterly Dividend; 07/05/2018 – PHIBRO ANIMAL 3Q ADJ EPS 46C, EST. 42C; 07/05/2018 – PHIBRO ANIMAL HEALTH CORP PAHC.O FY2018 SHR VIEW $1.69, REV VIEW $810.9 MLN — THOMSON REUTERS l/B/E/S; 20/04/2018 – Phibro Animal Presenting at Bank of America Conference May 16; 02/04/2018 – Thornburg Value Adds Starbucks, Exits Phibro Animal; 15/05/2018 – Phibro Animal Presenting at Bank of America Conference Tomorrow; 07/05/2018 – Phibro Animal Health 3Q EPS 49c

Since August 21, 2018, it had 0 buys, and 14 selling transactions for $7.35 million activity. $110,750 worth of Phibro Animal Health Corporation (NASDAQ:PAHC) was sold by Bendheim Daniel M on Wednesday, September 12. The insider BENDHEIM JACK sold $23,421. On Wednesday, September 5 BFI Co. – LLC sold $942,718 worth of Phibro Animal Health Corporation (NASDAQ:PAHC) or 20,000 shares. Warras Dean J also sold $685,824 worth of Phibro Animal Health Corporation (NASDAQ:PAHC) shares.

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition firm primarily in the United States. The company has market cap of $1.17 billion. It operates through three divisions: Animal Health, Mineral Nutrition, and Performance Products. It has a 15.92 P/E ratio. The firm develops, makes, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.

Investors sentiment increased to 2 in Q3 2018. Its up 0.41, from 1.59 in 2018Q2. It is positive, as 10 investors sold Phibro Animal Health Corporation shares while 41 reduced holdings. 35 funds opened positions while 67 raised stakes. 18.86 million shares or 2.25% more from 18.45 million shares in 2018Q2 were reported. Alliancebernstein Limited Partnership holds 0% in Phibro Animal Health Corporation (NASDAQ:PAHC) or 65,520 shares. First Quadrant Limited Partnership Ca stated it has 11,646 shares or 0.01% of all its holdings. Texas Permanent School Fund invested in 12,661 shares or 0.01% of the stock. Us Financial Bank De holds 0% of its portfolio in Phibro Animal Health Corporation (NASDAQ:PAHC) for 2,731 shares. Meeder Asset Management Inc holds 6,028 shares or 0.02% of its portfolio. Bank & Trust Of America De has invested 0% of its portfolio in Phibro Animal Health Corporation (NASDAQ:PAHC). Mason Street Lc invested in 5,962 shares. Dana Inv Advsrs Inc accumulated 6,330 shares. California-based Stevens First Principles Invest Advsr has invested 0.44% in Phibro Animal Health Corporation (NASDAQ:PAHC). Geode Llc holds 0% or 236,166 shares in its portfolio. State Of Wisconsin Invest Board holds 20,300 shares or 0% of its portfolio. Swiss Bankshares holds 0% or 33,600 shares in its portfolio. Moreover, Smith Asset Mgmt Grp L P has 0.02% invested in Phibro Animal Health Corporation (NASDAQ:PAHC). First Hawaiian Bankshares owns 1,269 shares. Pub Sector Pension Investment Board reported 13,840 shares.

More notable recent Phibro Animal Health Corporation (NASDAQ:PAHC) news were published by: Globenewswire.com which released: “Phibro Animal Health Corporation Reports Second Quarter Results – GlobeNewswire” on February 06, 2019, also Nasdaq.com with their article: “Report: Exploring Fundamental Drivers Behind Comcast, Rayonier, Clean Energy Fuels, Phibro Animal Health, First Cash, and Playa Hotels & Resorts NV — New Horizons, Emerging Trends, and Upcoming Developments – Nasdaq” published on February 08, 2019, Nasdaq.com published: “Phibro Animal Health Corporation to Participate in Bank of America Merrill Lynch 2019 Animal Health Summit – Nasdaq” on January 28, 2019. More interesting news about Phibro Animal Health Corporation (NASDAQ:PAHC) were released by: Nasdaq.com and their article: “Mid-Day ETF Update: ETFs, Stocks In the Red on Weak Earnings in Consumer, Tech Sectors; Jobless Claims Miss Estimates – Nasdaq” published on February 07, 2019 as well as Seekingalpha.com‘s news article titled: “Phibro Animal Health acquires KoVax – Seeking Alpha” with publication date: December 06, 2018.

Investors sentiment decreased to 1.09 in 2018 Q3. Its down 0.39, from 1.48 in 2018Q2. It worsened, as 22 investors sold AGIO shares while 54 reduced holdings. 26 funds opened positions while 57 raised stakes. 52.38 million shares or 0.04% more from 52.36 million shares in 2018Q2 were reported. Barrett Asset Management Ltd Liability Com holds 0.02% or 3,000 shares in its portfolio. 143,579 are held by Hood River Cap Management Limited Liability Com. Moreover, Lord Abbett & Limited Liability Corporation has 0.11% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 496,973 shares. Jane Street Grp Ltd Llc reported 0% stake. Fernwood Management Ltd Com stated it has 1.03% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Moreover, S&Co has 0.03% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 3,400 shares. Schwab Charles Mngmt stated it has 0.01% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Great West Life Assurance Can stated it has 0% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Asset One reported 0% stake. Vanguard Grp Inc stated it has 0.01% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Weiss Asset Limited Partnership reported 0.04% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Utah Retirement Systems has 0.01% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Riverhead Cap Management Llc reported 149 shares stake. Walleye Trading Ltd Limited Liability Company stated it has 103 shares. Axiom International Investors Limited Company De has 0.05% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Btg Pactual Global Asset Management Ltd increased Aetna Inc New (NYSE:AET) stake by 20,000 shares to 87,946 valued at $17.84 million in 2018Q3. It also upped Andeavor stake by 25,000 shares and now owns 52,736 shares. Mercadolibre Inc (NASDAQ:MELI) was raised too.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Seekingalpha.com which released: “Agios Pharmaceuticals Q4 2018 Earnings Preview – Seeking Alpha” on February 13, 2019, also Nasdaq.com with their article: “Agios to Webcast Conference Call of Fourth Quarter and Full Year 2018 Financial Results on February 14, 2019 – Nasdaq” published on January 31, 2019, Nasdaq.com published: “Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week’s Release – Nasdaq” on February 07, 2019. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Nasdaq.com and their article: “Agios Pharmaceuticals is Now Oversold (AGIO) – Nasdaq” published on December 20, 2018 as well as Bizjournals.com‘s news article titled: “Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup – Boston Business Journal” with publication date: January 18, 2019.

Phibro Animal Health Corporation (NASDAQ:PAHC) Institutional Positions Chart